Navigation Links
Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
Date:1/7/2009

UCB's Keppra XR Will Become the Gold Standard Adjunctive Treatment for Partial-Onset Epilepsy by 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists would welcome an adjunctive antiepileptic drug (AED) that is administered once-daily. According to U.S. neurologists, a drug of this type would earn a 25 percent patient share in epilepsy and according to European neurologists, such an agent would earn 35 percent patient share. According to the new report entitled Epilepsy: Opportunity Exists for Improved AEDs Despite Numerous Market Pressures, these robust patient shares highlight surveyed neurologists' keen interest in AEDs with less-frequent dosing. Nevertheless, these patient shares are considerably higher than those typically attained by adjunctive AEDs, given neurologists' generally conservative adoption of new epilepsy therapies as well as adjunctive AEDs' use primarily in refractory patients. Consequently, it is not expected that emerging adjunctive AEDs will capture such generous patient shares.

The report also finds that UCB's Keppra XR will earn Decision Resources' proprietary clinical gold standard status for the adjunctive treatment of partial-onset epilepsy by 2012 as interviewed specialists indicate that the drug has competitive advantages in safety and delivery attributes over GlaxoSmithKline's sales-leading Lamictal. According to surveyed neurologists, Keppra XR is perceived as having a lower risk of serious side effects and offers the advantage of once-daily dosing, which is considered to be the ideal AED dosing frequency for epilepsy patients.

"With its high cost and the high level of physician comfort in prescribing the drug as an add-on therapy, Lamictal became the epilepsy sales leader in 200
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
2. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
3. Morgan Fairchild Joins Neurologists, Emergency Physicians and the American Stroke Association to Educate the Public About Stroke Symptoms
4. Despite Availability of Generic Equivalents, Two-Thirds of Neurologists Will Continue to Prescribe Branded Anti-Epileptic Drugs to Epilepsy Patients
5. Eligard(R) six-month formulation successfully completes European approval procedure
6. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
7. Medical Services International Inc. Completes Testing for European Union (EU) Application
8. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
9. Europe-wide Researchers Night
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Launch of second European Cancer Research Funding survey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 The Best Hospitals ... Report consists of seven hospitals using OnBase as their ... and Cleveland Clinic were ranked at the top of ... The rankings cover nearly 5,000 medical centers across the ... hospitals that scored highest in at least six of ...
(Date:9/15/2014)... Randy Dotinga HealthDay Reporter ... Patients prescribed cholesterol-lowering drugs are more likely to fill ... are cheaper generic brands, new research suggests. At ... brands include Crestor, Zocor and Lipitor. Generic statins are ... risk of heart problems due to clogged arteries. ...
(Date:9/15/2014)... Worth, FL (PRWEB) September 15, 2014 ... policy away from putting low-level offenders in jail and ... Treatment Group sees this shift as a positive change. ... of prescription drug and heroin abuse. According to an ... both parties are calling for a shift away from ...
(Date:9/15/2014)... By Dennis Thompson ... (HealthDay News) -- The severe respiratory virus believed to ... Western states has now spread to the Northeast, health ... Health confirmed on Friday more than a dozen cases ... especially for children with asthma. And on Saturday, ...
(Date:9/15/2014)... 15, 2014 Array Health ... technology, today announced that Independence Blue Cross ... southeastern Pennsylvania, has selected the Array Spectrum™ Private ... exchange marketplace for employers with more than 100 ... Spectrum™, Independence will offer employer groups a comprehensive ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 3Health News:White House Shifts Policy on Drugs 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 2Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 3
... East Hills, NY (Sept. 19, 2007) -- Each year ... critical part of their donation literally go down the ... collected annually, a majority (about two-thirds) of the four ... banks are replacing this valuable resource with much more ...
... Former Speaker of the,House and founder of the ... of conservative Republican lawmakers on Capitol Hill,today that while ... over the State Children,s Health Insurance Program (SCHIP) is ... insistent that Congress,not lose sight of the hundreds of ...
... Inc.,(OTC: ABOS) today announced Walter C. Ogier has resigned as ... of Directors. The Arbios Board,of Directors has appointed Shawn P. ... and CEO. The Company plans to,initiate a search for a ... Board of Directors has elected Amy,Factor as Vice Chairman. Ms. ...
... The majority of parents feel they play a ... according to researchers at the University of Michigan C.S. ... in the October issue of the Journal of Pediatrics, ... decisions made about their hospitalized childs medical care. Researchers ...
... million Americans who are living with cancer or have ... keeping their spirits intact: communication. In recognition of this, ... report by November 1, co-authored by a University of ... to good cancer care and deserves more research. , ...
... factor found at higher levels in these tumors, scientists say ... called nerve growth factor (NGF) may prove an effective target ... NGF is an essential component in the growth and differentiation ... in the Oct. 7 issue of the World Journal ...
Cached Medicine News:Health News:Critical blood shortages eased by new technology 2Health News:Critical blood shortages eased by new technology 3Health News:Center for Health Transformation Founder Newt Gingrich Calls on Congress to Pass a 'Clean' SCHIP Six-Month Extension 2Health News:Arbios Announces Management Changes 2Health News:Parents' participation in medical decisions linked to self-efficacy 2Health News:Communication in cancer world is key to survival 2
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- Asthma is a chronic ... ages, but most commonly starts in childhood. It ... of the airways, leading to airflow limitation and ... contact with endogenous and exogenous irritants. Exposure to ... swelling of the airways, tightening of the respiratory ...
(Date:9/15/2014)... BRUSSELS , Sept. 15, 2014 Amgen ... today announced results from several exploratory analyses of the ... low bone mineral density (BMD). Romosozumab is an investigational ... the protein sclerostin, thereby increasing bone formation and decreasing ... Society for Bone and Mineral Research (ASBMR) 2014 Annual ...
(Date:9/15/2014)... 2014 myMatrixx has extended its contract with ... an expanded role that includes direct involvement in the ... nationally recognized physiatrist and pain management specialist, published author, ... workers, compensation, is Board Certified in physical medicine and ... Pain Medicine and subspecialty boarded by the American Board ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: